NFKB1 and B-cell chronic lymphocytic leukemia: Phase 2 (CAPTIVATE; NCT02910583) and phase 3 (GLOW; NCT03462719) clinical trials of ibrutinib and venetoclax combination for CLL have shown promising clinical results, highlighting the therapeutic potential of concurrently inhibiting BCR → NF-κB signaling and apoptotic signaling in CLL [60,61].